GSE153158 NF-kB knockout U-937 0 v 2 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE153158_NF-kB knockout_U-937_0_v_2_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE153158_NF-kB knockout_U-937_0_v_2_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE153158_NF-kB knockout_U-937_0_v_2_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE153158_NF-kB knockout_U-937_0_v_2_human_up.

Results found

Linked to

 

Label

Description

 

Gene

MIR1915 host gene

Gene

CD44 divergent transcript

Gene

RNA, 7SL, cytoplasmic 4, pseudogene

Gene

TMEM92 antisense RNA 1

Gene

long intergenic non-protein coding RNA 1622

Gene

long intergenic non-protein coding RNA 1910

Gene

ribosomal protein L5 pseudogene 34

Gene

secretory blood group 1, pseudogene

Gene

TTC36 and KMT2A antisense RNA 1

Gene

ribosomal protein SA pseudogene 54


  • Gene

    CD44 divergent transcript


  • Gene

    RNA, 7SL, cytoplasmic 4, pseudogene


  • Gene

    TMEM92 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 1622


  • Gene

    long intergenic non-protein coding RNA 1910


  • Gene

    ribosomal protein L5 pseudogene 34


  • Gene

    secretory blood group 1, pseudogene


  • Gene

    TTC36 and KMT2A antisense RNA 1


  • Gene

    ribosomal protein SA pseudogene 54

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.